DOCSLIB.ORG

Use of Methotrexate in Patients with Scleroderma and Mixed Connective Tissue Disease O

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Use of Methotrexate in Patients with Scleroderma and Mixed Connective Tissue Disease O Use of methotrexate in patients with scleroderma and mixed connective tissue disease O. Kowal-Bielecka1 and O. Distler2 1Department of Rheumatology and Internal ABSTRACT cal trials. Methotrexate (MTX), which Medicine, Medical University of Bialystok, Systemic sclerosis (scleroderma, SSc) proved effective in rheumatoid arthritis Poland; and mixed connective tissue disease (3 and reviewed in other chapters of 2Department of Rheumatology, University (MCTD) are chronic autoimmune dis- this issue), is also considered an op- Hospital Zurich, Switzerland. eases characterised by a broad spec- tion in treating SSc and MCTD. In the Otylia Kowal-Bielecka, MD trum of clinical manifestations includ- present review we discuss the available Oliver Distler, MD ing different forms of musculoskeletal evidence concerning usage of MTX in Please address correspondence involvement, skin and vascular chang- and reprint requests to: SSc and MCTD. Oliver Distler, MD, es, as well as internal organ complica- Department of Rheumatology, tions. Clinical course and outcomes Use of methotrexate in University Hospital Zurich, might vary from mild forms with good systemic sclerosis Gloriastrasse 25, clinical prognosis to severe rapidly Background 8091 Zurich, Switzerland. progressive life-threatening diseases. Systemic sclerosis (scleroderma, SSc) is E-mail: [email protected] At present, immunosuppressive thera- a multisystem connective tissue disease Received and accepted on July 24, 2010. pies are considered a cornerstone in characterised by widespread vasculop- Clin Exp Rheumatol 2010; 28 (Suppl. 61): the treatment of MCTD, and are fre- athy and profound fibrosis of the skin S160-S163. quently used in clinical practice in SSc and internal organs. Involvement of in- © Copyright CLINICAL AND despite limited evidence from clinical ternal organs, such as the lungs, heart, EXPERIMENTAL RHEUMATOLOGY 2010. trials. The aim of the present review is gastrointestinal tract and/or the kidneys to discuss available data concerning results in high morbidity and mortality Key words: Methotrexate, systemic efficacy of methotrexate therapy in SSc in SSc patients. At present, pulmonary sclerosis, mixed connective tissue and MCTD. complications including interstitial disease. lung disease (pulmonary fibrosis) and Introduction pulmonary arterial hypertension are Systemic sclerosis (scleroderma, SSc) the leading causes of death accounting and mixed connective tissue disease together for almost 60% of disease-re- (MCTD) are autoimmune diseases lated mortality in SSc patients (4). characterised by a broad spectrum of The natural clinical course of dis- clinical manifestations including dif- ease might vary. There are two major ferent forms of musculoskeletal in- forms of the disease: limited cutaneous volvement, skin changes, as well as in- SSc (lSSc) and diffuse cutaneous SSc ternal organ complications (1, 2). The (dSSc), which differ with respect to natural history of the disease and clini- extent and progression of skin thicken- cal outcome are highly variable in both ing, but also with respect to a pattern SSc and MCTD. Some patients have a of internal organ involvement and life mild, slowly progressive or self-lim- expectancy (5). ited disease, whereas others develop In patients with lSSc skin changes are major organ involvement that requires limited to face and distal parts of the aggressive treatment. No universal extremities, the disease progress is slow disease-modifying drugs are available and severe internal organ involvement for SSc and MCTD, and it is generally (usually interstitial lung disease or pul- agreed that treatment depends on each monary arterial hypertension) develop patient’s clinical involvement (organ- at later stages, often after several years targeted therapy). Clinical heteroge- from first symptoms attributable to SSc. neity is one of the main obstacles in In patients with dSSc skin thickening performing clinical trials in SSc and is much more extensive spreading from MCTD and for these reasons only a the distal parts to the arms, thighs and few therapies have proved effective the trunk, the pace of skin changes is Competing interests: none declared. in disease-specific randomised clini- much more rapid, especially in the first S-160 Use of methotrexate in patients with SSc and MCTD / O. Kowal-Bielecka & O. Distler years of the disease, and severe inter- Patients were evaluated in a double- temporary MTX withdrawal and did nal organ involvement (usually inter- blind manner and clinical response to not increase after resuming MTX. stitial lung disease, renal failure, heart treatment was defined as improvement Another larger multicenter double- or gastrointestinal involvement) might by at least 30% in total skin score, by at blind randomised trial included 71 develop early. least 15% in DLCO or by at least 50% patients with early dSSc of less than 3 Although destructive arthritis is uncom- in visual analogue scale (VAS) of well years duration, 35 of whom received mon in SSc, musculoskeletal involve- being, provided that such improve- MTX (orally 15mg-17.5mg/d) and 36 ment is frequent in SSc and includes ment was not accompanied by persist- received placebo (8). After 12 months, joint pain, joint contractures due to skin ing digital ulcerations or decrease in an intent-to-treat analysis showed im- changes, non-erosive arthritis, tendon DLCO by at least 15%. Twenty-five provement in skin scores in the MTX friction rub, myopathy and myositis out of 29 patients completed 24 weeks group (p<0.04 for the University of (1). SSc can also occur co-existing with of treatment. In the completers, fa- California Los Angeles (UCLA) skin other fully developed autoimmune dis- vourable response to treatment/clini- score and p<0.09 for the modified Rod- eases such as rheumatoid arthritis or cal improvement was seen more fre- nan skin score (mRSS)) versus pla- polymyositis; this situation is often re- quently in patients receiving MTX cebo. The mean changes in skin scores ferred to as overlap syndromes (2). (eight out of 15=53%) when compared were rather small (-1.2 for UCLA and Factors triggering SSc are not known. with the placebo-treated group (one -4.3 for mRSS in the MTX group com- Although the pathogenesis of SSc is not out of ten=10%, p=0.03). The favour- pared with 1.2 and 1.8 in the placebo fully clarified, clinical and experimental able response to treatment was due to group, respectively, p<0.05 for both evidence indicates that autoimmunity, skin score improvement in 3 patients, UCLA and mRSS), and the difference vascular injury and excessive produc- VAS improvement in 4 patients, and in the UCLA score lost its significance tion of connective tissue play key roles both skin and VAS improvement in 1 after adjustment for use of steroids and in the development and progression of patient. An intent-to-treat analysis of sex differences (p<0.07). MTX ap- the disease (6). Understanding of the single variables revealed a trend to- peared also to better preserve diffusing processes involved in SSc pathogenesis wards improvement of skin score and capacity of the lungs (DLCO) (p<0.03 led to design of treatment strategies. creatinine clearance in the MTX group for between group comparison at 12 Accordingly, recognition of the pres- at week 24 (p=-0.06 and p=0.07 versus months), however, the mean DLCO ence of autoimmune phenomenon in placebo, respectively). changes were small and did not differ SSc, such as the presence of autoanti- An extension study of another 24 significantly (-3.7% in MTX group vs. bodies, associations between specific weeks, during which MTX was given at -7.7% in placebo group, p<0.14). autoantibodies and particular disease 15mg/week in 9 MTX responders and No significant effect could be seen with patterns/outcomes and the presence of in 9 patients from the placebo group, or regard to other outcome measures, in- perivascular inflammatory mononuclear increased up to 25mg/week in 6 MTX cluding oral opening, grip strength, cell infiltration in the skin and internal non-responders, revealed improvement flexion index, functional index, HAQ or organs in early diffuse rapidly progres- in skin score and/or VAS in 15 out of patient global assessment. sive SSc, have led to the usage of im- 23 (68%) patients who completed 48 Thirteen (37%) patients withdraw from munosuppressive therapies in SSc. weeks. No significant differences in the MTX group and 11 (31%) patients clinical variables could, however, be from the placebo group, mainly due Clinical studies of methotrexate identified at week 48 when compared to treatment inefficacy. Only 1 patient in SSc with baseline values. Laboratory evalu- dropped out because of adverse event So far, the results of two multicentre ation revealed significant decrease in (oral ulcers on MTX treatment). randomised clinical trials investigating haemoglobin, white blood cells, plate- In summary, the results of the two ran- the efficacy and safety of MTX in SSc lets and IgG levels, when compared domised controlled trials (RCTs) indi- have been published (7, 8). with baseline values. cate that MTX improves skin changes The first trial involved 29 SSc patients Six patients (21%) withdrew from the in early dSSc. However, its clinical with early disease, defined as disease study during 48 weeks: four due to SSc- effect is of borderline value. No sig- duration shorter than 3 years from first related causes (death or renal crisis), 1 nificant improvement in internal organ signs of skin thickening. Patients with due to sudden death and 1 due to side manifestations could be demonstrated longer disease duration were also in- effects of treatment (persistent, severe with MTX therapy. The withdrawal cluded if they had experienced progres- headache after each injection). One rate was high in both trials, mainly due sion of skin thickening, persistent digital patient, who subsequently died due to treatment inefficacy or SSc-related ulcerations, or deterioration in pulmo- to severe interstitial lung disease, had complications. Toxicity of MTX was nary function during the last 6 months.
Load more

Recommended publications
  • Myositis Center Myositis Center
    About The Johns Hopkins The Johns Hopkins Myositis Center Myositis Center he Johns Hopkins Myositis Center, one Tof the first multidisciplinary centers of its kind that focuses on the diagnosis and management of myositis, combines the ex - pertise of rheumatologists, neurologists and pulmonologists who are committed to the treatment of this rare disease. The Center is conveniently located at Johns Hopkins Bayview Medical Center in Baltimore, Maryland. Patients referred to the Myositis Center can expect: • Multidisciplinary Care: Johns Hopkins Myositis Center specialists make a diagno - sis after evaluating each patient and re - viewing results of tests that include muscle enzyme levels, electromyography, muscle biopsy, pulmonary function and MRI. The Center brings together not only physicians with extensive experience in di - agnosing, researching and treating myosi - tis, but nutritionists and physical and occupational therapists as well. • Convenience: Same-day testing and appointments with multiple specialists are The Johns Hopkins typically scheduled to minimize doctor Myositis Center visits and avoid delays in diagnosis and Johns Hopkins Bayview Medical Center treatment. Mason F. Lord Building, Center Tower 5200 Eastern Avenue, Suite 4500 • Community: Because myositis is so rare, Baltimore, MD 21224 the Center provides a much-needed oppor - tunity for patients to meet other myositis patients, learn more about the disease and Physician and Patient Referrals: 410-550-6962 be continually updated on breakthroughs Fax: 410-550-3542 regarding treatment options. www.hopkinsmedicine.org/myositis The Johns Hopkins Myositis Center THE CENTER BRINGS TOGETHER Team NOT ONLY PHYSICIANS WITH EXTENSIVE EXPERIENCE IN DIAGNOSING , RESEARCHING AND Lisa Christophe r-Stine, TREATING MYOSITIS , BUT M.D., M.P.H.
    [Show full text]
  • Focal Eosinophilic Myositis Presenting with Leg Pain and Tenderness
    CASE REPORT Ann Clin Neurophysiol 2020;22(2):125-128 https://doi.org/10.14253/acn.2020.22.2.125 ANNALS OF CLINICAL NEUROPHYSIOLOGY Focal eosinophilic myositis presenting with leg pain and tenderness Jin-Hong Shin1,2, Dae-Seong Kim1,2 1Department of Neurology, Research Institute for Convergence of Biomedical Research, Pusan National University Yangsan Hospital, Yangsan, Korea 2Department of Neurology, Pusan National University School of Medicine, Yangsan, Korea Focal eosinophilic myositis (FEM) is the most limited form of eosinophilic myositis that com- Received: September 11, 2020 monly affects the muscles of the lower leg without systemic manifestations. We report a Revised: September 29, 2020 patient with FEM who was studied by magnetic resonance imaging and muscle biopsy with Accepted: September 29, 2020 a review of the literature. Key words: Myositis; Eosinophils; Magnetic resonance imaging Correspondence to Dae-Seong Kim Eosinophilic myositis (EM) is defined as a group of idiopathic inflammatory myopathies Department of Neurology, Pusan National associated with peripheral and/or intramuscular eosinophilia.1 Focal eosinophilic myositis Univeristy School of Medicine, 20 Geu- mo-ro, Mulgeum-eup, Yangsan 50612, (FEM) is the most limited form of EM and is considered a benign disorder without systemic 2 Korea manifestations. Here, we report a patient with localized leg pain and tenderness who was Tel: +82-55-360-2450 diagnosed as FEM based on laboratory findings, magnetic resonance imaging (MRI), and Fax: +82-55-360-2152 muscle biopsy. E-mail: [email protected] ORCID CASE Jin-Hong Shin https://orcid.org/0000-0002-5174-286X A 26-year-old otherwise healthy man visited our outpatient clinic with leg pain for Dae-Seong Kim 3 months.
    [Show full text]
  • The Impact of Hypermobility Spectrum Disorders on Musculoskeletal Tissue Stiffness: an Exploration Using Strain Elastography
    Clinical Rheumatology (2019) 38:85–95 https://doi.org/10.1007/s10067-018-4193-0 ORIGINAL ARTICLE The impact of hypermobility spectrum disorders on musculoskeletal tissue stiffness: an exploration using strain elastography Najla Alsiri1 & Saud Al-Obaidi2 & Akram Asbeutah2 & Mariam Almandeel1 & Shea Palmer3 Received: 24 January 2018 /Revised: 13 June 2018 /Accepted: 26 June 2018 /Published online: 3 July 2018 # International League of Associations for Rheumatology (ILAR) 2018 Abstract Hypermobility spectrum disorders (HSDs) are conditions associated with chronic joint pain and laxity. HSD’s diagnostic approach is highly subjective, its validity is not well studied, and it does not consider many of the most commonly affected joints. Strain elastography (SEL) reflects musculoskeletal elasticity with sonographic images. The study explored the impact of HSD on musculoskeletal elasticity using SEL. A cross-sectional design compared 21 participants with HSD against 22 controls. SEL was used to assess the elasticity of the deltoid, biceps brachii, brachioradialis, rectus femoris, and gastrocnemius muscles, and the patellar and Achilles tendon. SEL images were analyzed using strain index, strain ratio, and color pixels. Mean strain index (standard deviation) was significantly reduced in the HSD group compared to the control group in the brachioradialis muscle 0.43 (0.10) vs. 0.59 (0.24), patellar 0.30 (0.10) vs. 0.44 (0.11), and Achilles tendons 0.24 (0.06) vs. 0.49 (0.13). Brachioradialis muscle and patellar tendon’s strain ratios were significantly lower in the HSD group compared to the control group, 6.02 (2.11) vs. 8.68 (2.67) and 5.18 (1.67) vs.
    [Show full text]
  • Scleroderma, Myositis and Related Syndromes [4] Giordano J, Khung S, Duhamel A, Hossein-Foucher C, Bellèvre D, Lam- Blin N, Et Al
    Scientific Abstracts 1229 Ann Rheum Dis: first published as 10.1136/annrheumdis-2021-eular.75 on 19 May 2021. Downloaded from Scleroderma, myositis and related syndromes [4] Giordano J, Khung S, Duhamel A, Hossein-Foucher C, Bellèvre D, Lam- blin N, et al. Lung perfusion characteristics in pulmonary arterial hyper- tension and peripheral forms of chronic thromboembolic pulmonary AB0401 CAN DUAL-ENERGY CT LUNG PERFUSION hypertension: Dual-energy CT experience in 31 patients. Eur Radiol. 2017 DETECT ABNORMALITIES AT THE LEVEL OF LUNG Apr;27(4):1631–9. CIRCULATION IN SYSTEMIC SCLEROSIS (SSC)? Disclosure of Interests: None declared PRELIMINARY EXPERIENCE IN 101 PATIENTS DOI: 10.1136/annrheumdis-2021-eular.69 V. Koether1,2, A. Dupont3, J. Labreuche4, P. Felloni3, T. Perez3, P. Degroote5, E. Hachulla1,2,6, J. Remy3, M. Remy-Jardin3, D. Launay1,2,6. 1Lille, CHU Lille, AB0402 SELF-ASSESSMENT OF SCLERODERMA SKIN Service de Médecine Interne et Immunologie Clinique, Centre de référence THICKNESS: DEVELOPMENT AND VALIDATION OF des maladies autoimmunes systémiques rares du Nord et Nord-Ouest de THE PASTUL QUESTIONNAIRE 2 France (CeRAINO), Lille, France; Lille, Université de Lille, U1286 - INFINITE 1,2 1 1 1 J. Spierings , V. Ong , C. Denton . Royal Free and University College - Institute for Translational Research in Inflammation, Lille, France; 3Lille, Medical School, University College London, Division of Medicine, Department From the Department of Thoracic Imaging, Hôpital Calmette, Lille, France; 4 of Inflammation, Centre for Rheumatology and Connective
    [Show full text]
  • Myositis 101
    MYOSITIS 101 Your guide to understanding myositis Patients who are informed, who seek out other patients, and who develop helpful ways of communicating with their doctors have better outcomes. Because the disease is so rare, TMA seeks to provide as much information as possible to myositis patients so they can understand the challenges of their disease as well as the options for treating it. The opinions expressed in this publication are not necessarily those of The Myositis Association. We do not endorse any product or treatment we report. We ask that you always check any treatment with your physician. Copyright 2012 by TMA, Inc. TABLE OF CONTENTS contents Myositis basics ...........................................................1 Diagnosis ....................................................................5 Blood tests .............................................................. 11 Common questions ................................................. 15 Treatment ................................................................ 19 Disease management.............................................. 25 Be an informed patient ............................................ 29 Glossary of terms .................................................... 33 1 MYOSITIS BASICS “Myositis” means general inflammation or swelling of the muscle. There are many causes: infection, muscle injury from medications, inherited diseases, disorders of electrolyte levels, and thyroid disease. Exercise can cause temporary muscle inflammation that improves after rest. myositis
    [Show full text]
  • PATIENT FACT SHEET Myopathies
    Inflammatory PATIENT FACT SHEET Myopathies Inflammatory myopathies are muscle diseases caused skin rashes also. Muscle pain is not a common symptom. by inflammation. They are autoimmune diseases where Some people can have breathing problems. the body’s immune system attacks its own muscles by People of all ages and races may get inflammatory mistake. The most common inflammatory myopathies are myopathies, but they’re rare. Children usually get them polymyositis and dermatomyositis. between ages 5 and 10. Adults usually get these diseases CONDITION Inflammatory myopathies cause muscle weakness, usually between 40 and 50. Women get inflammatory myopathies DESCRIPTION in the neck, shoulders and hips. Dermatomyositis causes twice as often as men. The most common sign of inflammatory myopathies is • Shortness of breath weakness in the large muscles of the shoulders, neck or • Cough hips. Inflammation damages tissue so you lose strength Dermatomyositis causes skin rashes that look like red or in these muscles. Inflammatory myopathies may cause purple spots on the eyelids, or scaly, red bumps on the problems like these: elbows, knuckles or knees. Children may also have white • Trouble climbing stairs, lifting objects over your head spots on their skin called calcinosis or vasculitis, a blood or getting out of a seat vessel inflammation that causes skin lesions. SIGNS/ • Choking while eating or intake of food into the lungs SYMPTOMS Diagnosing inflammatory myopathies starts with (Deltasone, Orasone), to reduce inflammation. Muscle a muscle strength exam. A rheumatologist may also enzymes usually return to normal at 4 to 6 weeks, and do blood tests to measure certain muscle enzymes or strength returns in 2 to 3 months.
    [Show full text]
  • Inflammatory Myopathies B
    Current Treatment Options in Neurology DOI 10.1007/s11940-010-0111-8 Neuromuscular Disorders Inflammatory Myopathies B. Jane Distad, MD*,1 Anthony A. Amato, MD 2 Michael D. Weiss, MD 1 Address *,1Department of Neurology, Neuromuscular Division, University of Washing- ton, School of Medicine, Seattle, WA 98195, USA E-mail: [email protected] E-mail: [email protected] 2Department of Neurology, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115, USA E-mail: [email protected] * Springer Science+Business Media, LLC 2011 Opinion statement The mainstay of treatment for the idiopathic inflammatory myopathies currently and traditionally has been therapeutics aimed at suppressing or modifying the immune system. Most therapies being used are directed towards polymyositis (PM) and dermatomyositis (DM), as there is yet to be efficacious treatment of any kind for inclusion body myositis (IBM), However, there are few randomized controlled studies supporting the use of such therapies even in PM and DM. Even in the absence of controlled studies, oral corticosteroids (in particular high-dose prednisone) continue to be the first-line medications used to manage these conditions. Second-line therapies include the addition of chronic, steroid-sparing immunosuppressive drugs such as azathioprine, methotrexate, cyclosporine, cyclophosphamide, and mycophenolate mofetil. These drugs are typically added when patients are on corticosteroids for an extended period or when the disease is refractory. Such medications often allow corticosteroid dosages to be reduced, but monitoring is required for their own side effects, such as bone marrow suppression, kidney dysfunction, and respiratory concerns. Small controlled studies also support the role of intravenous immunoglobulin therapy as an alternative therapy, particularly for DM, though the cost of this treatment is sometimes prohibitive.
    [Show full text]
  • Polymyositis / Dermatomyositis)
    Myositis (Polymyositis / Dermatomyositis) Myositis is a disease characterized by inflammation of the muscles and is often associated with severe muscle weakness. Myositis can also affect other organ systems including the skin, joints, lungs, heart, and gastrointestinal tract. It is a chronic disease, meaning it lasts a long time. The most common forms of myositis are polymyositis and dermatomyositis. Myositis is a systemic autoimmune disease. This means that the body’s natural immune system does not behave normally. Instead of serving to fight infections such as bacteria and viruses, the body’s own immune system attacks itself. In myositis, autoimmunity may cause the immune system to attack specific muscles resulting in muscle damage and destruction. The immune system may also attack other organs such as the lungs, skin, joints and gastrointestinal tract. What are Some of the Symptoms of Myositis? As an autoimmune disease that mostly targets muscles, myositis most obvious symptoms manifest themselves in muscle fatigue and pain. The disease may have many other symptoms. Common symptoms of myositis include: • Muscle weakness • Muscle pains • Rashes • Fatigue • Weight loss • Low-grade fevers • Arthritis • Color changes of hands and feet with cold exposure (known as Raynaud’s) • Difficulty swallowing • Heartburn • Cough • Shortness of breath Who Gets Myositis? Although myositis is a rare disease, people of all races and ethnic backgrounds get the disease. The peak age of onset is in the 50s, although it can occur at any age. Inclusion body myositis is more common in men, while dermatomyositis and polymyositis are more common in women. What Causes Myositis? The cause of myositis remains unknown.
    [Show full text]
  • 14.30 Dr Hector Chinoy
    Recent advances in myositis Dr Hector Chinoy PhD FRCP @drhectorchinoy Senior Lecturer / Honorary Consultant Rheumatologist Salford Royal NHS Foundation Trust Manchester Academic Health Science Centre The University of Manchester, UK Planned Layout what is myositis? how do we classify myositis? myositis disease spectrum antibodies case presentations how do we assess and treat myositis? Planned Layout what is myositis? how do we classify myositis? myositis disease spectrum antibodies case presentations how do we assess and treat myositis? Idiopathic inflammatory myopathy (IIM): A heterogeneous group of rare autoimmune muscle disorders Rare disease, annual Different IIM subtypes with incidence 5-10/million commonality of myositis 2 peaks of onset: Extra - muscular features (5-15 years) eg skin, lung, cardiac, (30-50 years) malignancy Patterns of disease Lack of evidence base for (rule of 1/3’s): treatment Monogenic Steroid & immunoresponsive Relapsing/remitting Treatment phases: induction/maintenance of remission Chronic persistent How do patients’ present with inflammatory myopathy? Insidious onset of proximal weakness Myalgia Fatigue Dysphagia Dyspnoea Weight loss Skin abnormalities (including ulceration) Raynaud’s Dry, cracked hands Arthralgia/arthritis Creatine Features of Myositis ATP ATP Creatine Kinase + ADP ADP + H Creatine phosphate Clues on bloods Low creatinine High ferritin High ALT Raised Troponin T Negative ANA Many causes of raised CK! 1. Muscle trauma a) Muscle injury / Needle stick b) EMG c) Surgery d) Convulsions, delirium tremens 2. Diseases affecting muscle a) Myocardial infarction f) Dystrophinopathies b) Rhabdomyolysis h) Amyotrophic lateral sclerosis g) Infectious myositis i) Neuromyotonias c) Metabolic myopathies h) Idiopathic inflammatory d) Carnitine palmityltransferase myopathy II deficiency e) Mitochondrial myopathies 3.
    [Show full text]
  • A Case of Dermatomyositis with Secondary Sjögren's Syndrome
    162 A Case of Dermatomyositis with Secondary Sjögren’s Syndrome- Diagnosis with Follow-up Study of Technetium-99m Pyrophosphate Scintigraphy Ching-Tang Huang1, Ying-Chu Chen1, Chingtsai Lin2, Yu-Chun Hsiao3, Lai-Fa Sheu4, Min-Chien Tu1 Abstract Purpose: To report a case of dermatomyositis (DM) with secondary Sjögren’s syndrome (SS) and propose the clinical application of technetium-99m pyrophosphate (99mTc-PYP) scan. Case Report: A 50-year-old woman had progressive proximal muscle weakness of bilateral thighs, myalgia, tea-colored urine, and exercise intolerance for 6 months. Physical examination showed malar rash, V-sign, periungual erythema, and mechanic hands. Neurological assessment showed symmetric pelvic-girdle weakness, myopathic face, waddling gait, but preserved deep tendon reflex and sensory functions. DM was diagnosed on the basis of typical rashes and serum creatinine kinase elevation (7397 IU/L). Aside from myopathic symptoms, dry eye and mouth were reported. Thorough autoantibody searches showed positive anti-SSA/Ro antibody (198 U/ml). Both Schirmer's test and sialoscintigraphy were positive, leading secondary SS as diagnosis. Initial 99mTc-PYP scan revealed increased radiouptake in the muscles of bilateral thighs, compatible with clinical assessment. Follow- up scan three months later shows abnormal but attenuated radiouptake at bilateral thighs, in the presence of nearly-complete clinical recovery. Conclusion: DM with secondary SS in adult is a unique disease entity, with predominantly myopathic symptoms and satisfactory therapeutic response as its characteristics. Our serial muscle imaging studies suggest that 99mTc-PYP scan is at once anatomically-specific and persistently-sensitive to microstructural damages within inflammatory muscles, enabling clinician to monitor disease activity and therapeutic response.
    [Show full text]
  • Redalyc.Muscle Strength Assessment Among Children and Adolescents
    Revista Brasileira de Fisioterapia ISSN: 1413-3555 [email protected] Associação Brasileira de Pesquisa e Pós- Graduação em Fisioterapia Brasil Marcolin, ALV; Cardin, SP; Magalhães, CS Muscle strength assessment among children and adolescents with growing pains and joint hypermobility Revista Brasileira de Fisioterapia, vol. 13, núm. 2, marzo-abril, 2009 Associação Brasileira de Pesquisa e Pós-Graduação em Fisioterapia São Carlos, Brasil Available in: http://www.redalyc.org/articulo.oa?id=235016468004 How to cite Complete issue Scientific Information System More information about this article Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal Journal's homepage in redalyc.org Non-profit academic project, developed under the open access initiative ISSN 1413-3555 Rev Bras Fisioter, São Carlos, v. 13,Rev n. 1,Bras p. X-XX,Fisioter, jan./fev. São Carlos 2009 ARTIGO ORIGIN A L ©Revista Brasileira de Fisioterapia Muscle strength assessment among children and adolescents with growing pains and joint hypermobility Avaliação da força muscular em crianças e adolescentes com dores de crescimento e hipermobilidade articular Marcolin ALV, Cardin SP, Magalhães CS Abstract Objective: To compare the muscle strength of children and adolescents with growing pains, with and without joint hypermobility, to healthy controls by means of quantitative tests. Method: Forty-seven children and adolescents were monitored because of growing pains: 24 with joint hypermobility (GP-JH group) and 23 without joint hypermobility (GP group). These cases, along with 47 healthy controls matched for age and gender, underwent two quantitative tests for muscle strength evaluation: the Childhood Myositis Assessment Scale (CMAS) and the Manual Muscle Strength Test (MMT).
    [Show full text]
  • How Lupus Affects the Muscles, Tendons and Joints
    How lupus affects the muscles, tendons and joints It is not uncommon for people with lupus to experience muscle aches and pain (myalgias) or have inflammation of certain muscle groups (myositis), which causes weakness and loss of strength. More than 90 percent of people with lupus will experience joint and/or muscle pain at some time during the course of their illness.1 More than half of the people who develop lupus mention joint pain as their first symptom. Muscle pain and muscle tenderness, especially during periods of increased disease activity (flare), occur in as many as 50 percent of those with lupus. The symptoms may have different causes. It is important for your physician to determine the cause of your symptoms since treatments are quite varied. Rheumatologists are the physicians who specialize in the joints, muscles and bones. Muscle aches and pain may be from symptoms that happen when your body is responding to some type of inflammation, from muscle atrophy (weakness) or from a true myositis. Inflammation Inflammation is the most common reason for muscle pain and aches. Any time that major inflammation exists ("strep" throat, hepatitis, cancer, lupus, acute heart attack, etc.), signs and symptoms often include fevers, sweats, chills, fatigue, weight loss, and various muscle aches, pains and weakness. These non-specific, non-diagnostic symptoms are signs of your body's inability to cope with whatever process has overwhelmed it. Because lupus is an inflammatory disease it may cause any of these problems. These myalgias are a secondary part of the overall disease. Lupus arthritis Lupus arthritis causes pain, stiffness, swelling, tenderness and warmth in your joints.
    [Show full text]